Association between Cyclooxygenase-2 gene polymorphisms and head and neck squamous cell carcinoma risk

Journal of Craniofacial Surgery

Volumn 25, Issue 2, 2014, Pages 333-337

  Niu, Yuming ^a   Yuan, Hua ^b   Shen, Ming ^b   Li, Huizhang ^b   Hu, Yuanyuan ^a   Chen, Ning ^b  

^a HUBEI UNIVERSITY OF MEDICINE   (China)

^b NANJING MEDICAL UNIVERSITY   (China)

Author keywords

COX 2; head and neck squamous cell carcinoma; polymorphism; susceptibility

Indexed keywords

EID: 84897103368     PISSN: 10492275     EISSN: 15363732     Source Type: Journal    
DOI: 10.1097/SCS.0000000000000372     Document Type: Article

References (42)

1. Argiris A, Eng C. Epidemiology, staging, and screening of head and neck cancer. Cancer Treat Res 2003;114:15-60
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108
3. Argiris A, KaramouzisMV, Raben D, et al. Head and neck cancer. Lancet 2008;371:1695-1709
4. Blot WJ, McLaughlin JK, Winn DM, et al. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res 1988;48:3282-3287
5. Vineis P, Alavanja M, Buffler P, et al. Tobacco and cancer: recent epidemiological evidence. J Natl Cancer Inst 2004;96:99-106
6. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-286
7. Romano M, Claria J. Cyclooxygenase-2 and 5-lipoxygenase converging functions on cell proliferation and tumor angiogenesis: implications for cancer therapy. FASEB J 2003;17:1986-1995
8. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacol Rev 2004;56:387-437
9. Vane SJ. Differential inhibition of cyclooxygenase isoforms: an explanation of the action of NSAIDs. J Clin Rheumatol 1998;4:s3-s10
10. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996;1299:125-140
11. Souza RF, Shewmake K, Beer DG, et al. Selective inhibition of cyclooxygenase-2 suppresses growth and induces apoptosis in human esophageal adenocarcinoma cells. Cancer Res 2000;60:5767-5772
12. Ranger GS, Thomas V, Jewell A, et al. Elevated cyclooxygenase-2 expression correlates with distant metastases in breast cancer. Anticancer Res 2004;24:2349-2351
13. Bayazit YA, Buyukberber S, Sari I, et al. Cyclo-oxygenase 2 expression in laryngeal squamous cell carcinoma and its clinical correlates. ORL J Otorhinolaryngol Relat Spec 2004;66:65-69
14. Segawa E, Sakurai K, Kishimoto H, et al. Expression of cyclooxygenase-2 and DNA topoisomerase II alpha in precancerous and cancerous lesions of the oral mucosa. Oral Oncol 2008;44:664-671
15. Liu X, Li P, Zhang ST, et al. COX-2 mRNA expression in esophageal squamous cell carcinoma (ESCC) and effect by NSAID. Dis Esophagus 2008;21:9-14
16. Gao J, Niwa K, Sun W, et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 2004;95:901-907
17. Kurihara Y, Hatori M, Ando Y, et al. Inhibition of cyclooxygenase-2 suppresses the invasiveness of oral squamous cell carcinoma cell lines via down-regulation of matrix metalloproteinase-2 production and activation. Clin Exp Metastasis 2009;26:425-432
18. Jeong SW, Tae K, Lee SH, et al. Cox-2 and IL-10 polymorphisms and association with squamous cell carcinoma of the head and neck in a Korean sample. J Korean Med Sci 2010;25:1024-1028
19. Peters WH, Lacko M, Te Morsche RH, et al. COX-2 polymorphisms and the risk for head and neck cancer in white patients. Head Neck 2009;31:938-943
20. Pu X, Lippman SM, Yang H, et al. Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. Cancer 2009;115:1498-1506
21. Chiang SL, Chen PH, Lee CH, et al. Up-regulation of inflammatory signalings by areca nut extract and role of cyclooxygenase-2-1195G9A polymorphism reveal risk of oral cancer. Cancer Res 2008;68: 8489-8498
22. Lin YC, Huang HI,Wang LH, et al. Polymorphisms of COX-2-765G9C and p53 codon 72 and risks of oral squamous cell carcinoma in a Taiwan population. Oral Oncol 2008;44:798-804
23. Campa D, Hashibe M, Zaridze D, et al. Association of common polymorphisms in inflammatory genes with risk of developing cancers of the upper aerodigestive tract. Cancer Causes Control 2007;18:449-455
24. Chu H, Cao W, Chen W, et al. Potentially functional polymorphisms in IL-23R and risk of esophageal cancer in a Chinese population. Int J Cancer 2011;130:1093-1097
25. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005;15:97-98
26. Secretan B, Straif K, Baan R, et al. A reviewof human carcinogensVPart E: tobacco, areca nut, alcohol, coal smoke, and salted fish. Lancet Oncol 2009;10:1033-1034
27. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006;24:2137-2150
28. Smith EM, Rubenstein LM, Haugen TH, et al. Tobacco and alcohol use increases the risk of both HPV-associated and HPV-independent head and neck cancers. Cancer Causes Control 2010;21:1369-1378
29. Guha N, Boffetta P, Wunsch Filho V, et al. Oral health and risk of squamous cell carcinoma of the head and neck and esophagus: results of two multicentric case-control studies. Am J Epidemiol 2007;166:1159-1173
30. Mayne ST, Cartmel B, Kirsh V, et al. Alcohol and tobacco use prediagnosis and postdiagnosis, and survival in a cohort of patients with early stage cancers of the oral cavity, pharynx, and larynx. Cancer Epidemiol Biomarkers Prev 2009;18:3368-3374
31. Seitz HK, Stickel F. Molecular mechanisms of alcohol-mediated carcinogenesis. Nat Rev Cancer 2007;7:599-612
32. Wang XD. Alcohol, vitamin A, and cancer. Alcohol 2005;35:251-258
33. D'Souza G, Kreimer AR, Viscidi R, et al. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med 2007;356: 1944-1956
34. Bisht M, Bist SS. Human papilloma virus: a new risk factor in a subset of head and neck cancers. J Cancer Res Ther 2011;7:251-255
35. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-7916
36. Wu T. Cyclooxygenase-2 and prostaglandin signaling in cholangiocarcinoma. Biochim Biophys Acta 2005;1755:135-150
37. Mittal M, Kapoor V, Mohanti BK, et al. Functional variants of COX-2 and risk of tobacco-related oral squamous cell carcinoma in high-risk Asian Indians. Oral Oncol 2010;46:622-626
38. Zhang X, Miao X, Tan W, et al. Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology 2005;129:565-576
39. Cok SJ, Morrison AR. The 3'-untranslated region of murine cyclooxygenase-2 contains multiple regulatory elements that alter message stability and translational efficiency. J Biol Chem 2001;276:23179-23185
40. Kuersten S, Goodwin EB. The power of the 3' UTR: translational control and development. Nat Rev Genet 2003;4:626-637
41. Shi J, Misso NL, Kedda MA, et al. Cyclooxygenase-2 gene polymorphisms in an Australian population: association of the-1195G 9A promoter polymorphism with mild asthma. Clin Exp Allergy 2008;38:913-920
42. Sakaki M, Makino R, Hiroishi K, et al. Cyclooxygenase-2 gene promoter polymorphisms affect susceptibility to hepatitis C virus infection and disease progression. Hepatol Res 2010;40:1219-1226